Get the Stockscreener App
17.41
4.88%
0.81
Odyssey Therapeutics Inc stock is traded at $17.41, with a volume of 53,547.
It is up +4.88% in the last 24 hours and down -20.83% over the past month.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
See More
Previous Close:
$16.60
Open:
$16.62
24h Volume:
53,547
Relative Volume:
0.19
Market Cap:
$836.70M
Revenue:
$3.96M
Net Income/Loss:
$-141.49M
P/E Ratio:
-5.6254
EPS:
-3.0949
Net Cash Flow:
1W Performance:
-3.92%
1M Performance:
-20.83%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.36
$17.75
1-Week Range:
$16.50
$19.65
52-Week Range:
$15.10
$29.05
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Name
Odyssey Therapeutics Inc
Sector
Industry
Phone
(212) 841-1000
Address
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
17.41 | 836.70M | 3.96M | -141.49M | 0 | -3.0949 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Odyssey Therapeutics Inc Stock (ODTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Initiated | UBS | Buy |
| Oct-09-26 | Initiated | Raymond James | Outperform |
| Aug-27-26 | Initiated | H.C. Wainwright | Buy |
| Jun-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-26 | Initiated | JP Morgan | Overweight |
| Jun-02-26 | Initiated | Oppenheimer | Outperform |
| Jun-02-26 | Initiated | TD Cowen | Buy |
| Jun-02-26 | Initiated | Wedbush | Outperform |
View All
Odyssey Therapeutics Inc Stock (ODTX) Latest News
UBS initiates Odyssey Therapeutics stock with buy rating on IBD drug - Investing.com Canada
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages - MarketBeat
State Street Corp Makes New $1.48 Million Investment in Odyssey Therapeutics, Inc. $ODTX - MarketBeat
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering - Yahoo Finance
Electra Therapeutics, Inc. Common stock (ETRA) stock price, news, quote and history - Yahoo Finance Australia
A biotech presentation is set for Sept. 23. Odyssey Therapeutics will take part online. - Stock Titan
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Odyssey Therapeutics’ OD-001 Meets Key Endpoints in Ulcerative Colitis Trial - Minichart
Oral ulcerative colitis drug at Odyssey (ODTX) put 27% of patients in remission—larger trials are planned - Stock Titan
Odyssey Therapeutics posts September 2026 presentation detailing OD-001 Phase 2a success, $433M cash runway into H2 2028 - TradingView
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
RIPK2 inhibitors reported in Odyssey Therapeutics patent - BioWorld News
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - Kalkine
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Eastern Progress
Q3 Earnings Forecast for ODTX Issued By HC Wainwright - MarketBeat
Odyssey Therapeutics, Inc. Common Stock (NASDAQ: ODTX) Stock Price, News & Analysis - kalkine.ca
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Moomoo
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Odyssey Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29 - Moomoo
Vogenx Announces Pricing of Initial Public Offering - Yahoo Finance
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention - Yahoo Finance
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - Sahm
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News Lands - simplywall.st
ODTX Forecast & Price Target - TradingKey
Evotec and Odyssey Forge AI-Powered Drug Discovery Pact Targeting Autoimmune Diseases - finance.biggo.com
Odyssey Therapeutics (NASDAQ:ODTX) Given New $29.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX) - theglobeandmail.com
EQS-News: Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - sharewise.com
Odyssey Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Odyssey Therapeutics: Q2 Earnings Snapshot - barchart.com
Odyssey Therapeutics, Inc. Q2 2026: Revenue $0 EPS $(1.74) — 10-Q Summary - TradingView
Biotech Stocks At 52-Week HighsBVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS - RTTNews
Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases - Stock Titan
Evotec Se and Odyssey Therapeutics, Inc. Enter Ai-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - Yahoo Finance
Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases - marketscreener.com
Odyssey Therapeutics (ODTX) Institutional Ownership 2026 - MarketBeat
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics reports Q2 2026 net loss $52.8M; cash $433.1M to fund into 2H 2028 - TradingView
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement - Yahoo Finance
Odyssey Therapeutics, Inc. Revenue Breakdown – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ODTX|Odyssey Therapeutics Ord Shs (Proposed)|Price:18.660|Chg%:+0.990 - TradingKey
Enterprise value to EBITDA forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Enterprise value to revenue forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to book forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to earnings forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Price to sales forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics Inc Stock (ODTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Odyssey Therapeutics Inc Stock (ODTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
5.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):